JUN and cancer: When we analyzed the DNA-bound JUN effects on the chromatin structure of CD47 or PD-L1, we noticed that JUN enrichment (by JUN ChIP-seq) occurs preferentially in a distal genomic region (shaded in green; previously shown to be a super-enhancer of CD47 in cancer)43 for CD47 and in the first intronic genomic region (shaded in green; reported as a PD-L1 active enhancer)44 for PD-L1, rather than in their corresponding promoters (shaded in red).